MX2020008718A - Anticuerpos de union a bcma y usos de los mismos. - Google Patents

Anticuerpos de union a bcma y usos de los mismos.

Info

Publication number
MX2020008718A
MX2020008718A MX2020008718A MX2020008718A MX2020008718A MX 2020008718 A MX2020008718 A MX 2020008718A MX 2020008718 A MX2020008718 A MX 2020008718A MX 2020008718 A MX2020008718 A MX 2020008718A MX 2020008718 A MX2020008718 A MX 2020008718A
Authority
MX
Mexico
Prior art keywords
bcma
patient
antibody species
binding antibodies
administering
Prior art date
Application number
MX2020008718A
Other languages
English (en)
Inventor
Jeonghoon Sun
Kandasamy Hariharan
Mahan Abbasian
Henry Chan
Andrew Wurmser
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2020008718A publication Critical patent/MX2020008718A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Se proporcionan especies de anticuerpos que se unen al Antígeno de Maduración de Células B (BCMA) así como también métodos para agotar células que expresan BCMA en un paciente que lo necesita, que comprenden administrar una cantidad terapéuticamente eficaz de las especies de anticuerpos o una entidad que comprende un fragmento de unión a BCMA de los mismos. Se proporcionan métodos para tratar trastornos relacionados con células B asociados con la expresión de BCMA en un paciente que lo necesita, que comprenden administrar al paciente una cantidad terapéuticamente eficaz de las especies de anticuerpos o una entidad que comprende un fragmento de unión a BCMA de los mismos.
MX2020008718A 2018-02-21 2019-02-20 Anticuerpos de union a bcma y usos de los mismos. MX2020008718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633152P 2018-02-21 2018-02-21
PCT/US2019/018698 WO2019164891A1 (en) 2018-02-21 2019-02-20 Bcma-binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020008718A true MX2020008718A (es) 2020-12-07

Family

ID=65686040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008718A MX2020008718A (es) 2018-02-21 2019-02-20 Anticuerpos de union a bcma y usos de los mismos.

Country Status (15)

Country Link
US (2) US11401336B2 (es)
EP (1) EP3755718A1 (es)
JP (1) JP2021514193A (es)
KR (1) KR20200123155A (es)
CN (1) CN112272675A (es)
AR (1) AR115257A1 (es)
AU (1) AU2019223076A1 (es)
BR (1) BR112020017053A2 (es)
CA (1) CA3092037A1 (es)
EA (1) EA202091974A1 (es)
IL (1) IL276548A (es)
MX (1) MX2020008718A (es)
SG (1) SG11202007495SA (es)
TW (1) TW202000701A (es)
WO (1) WO2019164891A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099944A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
MX2022013465A (es) * 2020-04-30 2023-01-11 Bristol Myers Squibb Co Metodos para tratar eventos adversos relacionados con citocinas.
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
WO1996028435A1 (en) 1995-03-10 1996-09-19 Hauser Chemical Research, Inc. Cephalomannine epoxide, its analogues and a method for preparing the same
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ES2529190T3 (es) 1996-07-24 2015-02-17 Celgene Corporation 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
ATE306469T1 (de) 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
EP1924250B1 (en) 2004-12-01 2017-01-04 Celgene Corporation Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders
JP2008528514A (ja) 2005-01-25 2008-07-31 セルジーン・コーポレーション ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物
CA2899923A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
JP2012502967A (ja) * 2008-09-19 2012-02-02 メディミューン，エルエルシー ソニック・ヘッジホッグホモログに対する抗体およびその使用
MX337169B (es) 2010-02-11 2016-02-16 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
SG192946A1 (en) 2011-03-11 2013-09-30 Celgene Corp Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
PT3415531T (pt) 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
ES2699810T3 (es) 2012-06-29 2019-02-12 Celgene Corp Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US10144782B2 (en) * 2014-04-30 2018-12-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Humanized antibodies against CD269 (BCMA)
CN106687483B (zh) * 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SI3628687T1 (sl) * 2014-12-12 2021-12-31 2Seventy Bio, Inc. BCMA himerni antigenski receptorji
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
PE20171653A1 (es) 2015-04-13 2017-11-13 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
KR20190008171A (ko) * 2015-11-13 2019-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
CN109414455B (zh) * 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
AU2017281034B2 (en) * 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies

Also Published As

Publication number Publication date
IL276548A (en) 2020-09-30
WO2019164891A1 (en) 2019-08-29
US11401336B2 (en) 2022-08-02
EA202091974A1 (ru) 2020-12-08
KR20200123155A (ko) 2020-10-28
TW202000701A (zh) 2020-01-01
WO2019164891A9 (en) 2020-09-17
JP2021514193A (ja) 2021-06-10
SG11202007495SA (en) 2020-09-29
EP3755718A1 (en) 2020-12-30
CN112272675A (zh) 2021-01-26
CA3092037A1 (en) 2019-08-29
US20220324991A1 (en) 2022-10-13
US20200399386A1 (en) 2020-12-24
AU2019223076A1 (en) 2020-10-08
AR115257A1 (es) 2020-12-16
BR112020017053A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MY185813A (en) Factor xi antibodies and methods of use
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
PH12019501087A1 (en) A pharmaceutical composition for averting opioid addiction
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
PH12020551454A1 (en) Anti-cd25 for tumour specific cell depletion
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof